• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-Q filed by Bio-Path Holdings Inc.

    11/17/25 3:07:55 PM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BPTH alert in real time by email
    NT 10-Q 1 nt_10q.htm EXTENSION

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

    FORM 12b-25

    NOTIFICATION OF LATE FILING

     

    ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form N-SAR

     

    For the Period Ended: September 30, 2025

     

    ☐ Transition Report on Form 10-KSB

    ☐ Transition Report on Form 10-QSB

    ☐ Transition Report on Form 20-F

    ☐ Transition Report on Form N-SAR

    ☐ Transition Report on Form 11-K

     

    For the Transition Period Ended:

     

    Nothing in this Form shall be construed to imply that the Commission has verified any information contained herein.

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

     

    PART I - REGISTRANT INFORMATION

     

    Full Name of Registrant: Bio-Path Holdings, Inc.

     

    Former Name, if Applicable: Not Applicable:

     

    Address of Principal Executive Office (Street and Number):

     

    625 Stanwix St. #2407

    Pittsburgh, PA 15222

     

     

     

     

    PART II - RULES 12b-25 (b) AND (c)

     

    If the subject report could not be filed without reasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

    ☐ (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

     

    ☒ (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

     

    ☐ (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable)

     

    PART III - NARRATIVE

     

    State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

     

    The Registrant is in the process of compiling information for the quarter ending September 30, 2025 for the Form 10-Q, all of which information has not yet been received due to change in management.

     

    PART IV - OTHER INFORMATION

     

    (1) Name and telephone number of person to contact in regard to this notification:

             
      Vikram Grover   630   708-0750
      (Name)   (Area Code)   (Telephone Number)

     

    (2) Have all or other periodic report required under section 13 or 15(d) of the Securities Exchange Act of 1934 or section 30 of the Investment Company act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).

     

    ☒ Yes ☐ No

     

    (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

     

    ☐ Yes ☒ No

     

     
     

     

    The Registrant has caused this notification to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      BIO-PATH HOLDINGS, INC.
    Dated: November 17, 2025  By: /s/ Vikram Grover
        Vikram Grover
        Chief Executive Officer, Chief Financial Officer and Director

     

    Get the next $BPTH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BPTH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BPTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Sherwood Aline

    4 - BIO-PATH HOLDINGS, INC. (0001133818) (Issuer)

    8/1/24 6:14:31 PM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Aubert Paul

    4 - BIO-PATH HOLDINGS, INC. (0001133818) (Issuer)

    8/1/24 6:10:56 PM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Cleaver Heath

    4 - BIO-PATH HOLDINGS, INC. (0001133818) (Issuer)

    8/1/24 6:07:55 PM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BPTH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Life Sciences Investor Forum: Now Available for Online Viewing

    NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Investor Forum, held June 11th and 12th are now available for online viewing. REGISTER AND VIEW PRESENTATIONS The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may downloadinvestor materials from the company's resource section. Select companies are accepting 1x1 management meeting requests through June 17. June 11th PresentationTicker(s)Nika Pharmaceuticals(OTCQB:NIKA)Tivic Health Systems Inc.(NASDAQ:TIVC)Ad

    6/13/25 8:35:00 AM ET
    $ATNM
    $BPTH
    $COCH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties
    Medical/Nursing Services

    Life Sciences Investor Forum Agenda Announced for June 11th-12th

    NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum June 11th & 12th. This event is co-hosted by Zacks Small Cap Research. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to log-in, attend live presentations, or schedule 1x1 meetings with management. "The life sciences sector is driving breakthrough innovation, and we're proud to give these pioneering co

    6/10/25 2:38:09 PM ET
    $ATNM
    $BPTH
    $COCH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties
    Medical/Nursing Services

    Bio-Path Holdings to Present at Life Sciences Virtual Investor Forum

    HOUSTON, June 09, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTC:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced Peter Nielsen, Chief Executive Officer, will present a corporate overview at the Life Sciences Virtual Investor Forum on Thursday, June 12 at 12:00 p.m. ET. A live stream of the presentation will be available here and on the Investor Relations section of Bio-Path's website, where it will be archived for approximately 90 days. About Bio-Path Holdings, Inc. Bio-Path is a biotechnology company developing DNAbilize®, a

    6/9/25 7:00:00 AM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BPTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on Bio-Path

    Roth Capital initiated coverage of Bio-Path with a rating of Buy

    3/11/21 7:29:52 AM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ROTH Capital initiated coverage on Bio-Path with a new price target

    ROTH Capital initiated coverage of Bio-Path with a rating of Buy and set a new price target of $13.00

    3/11/21 7:25:18 AM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BPTH
    SEC Filings

    View All

    SEC Form NT 10-Q filed by Bio-Path Holdings Inc.

    NT 10-Q - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)

    11/17/25 3:07:55 PM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bio-Path Holdings Inc. filed SEC Form 8-K: Leadership Update, Other Events

    8-K - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)

    11/14/25 12:10:42 PM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bio-Path Holdings Inc. filed SEC Form 8-K: Leadership Update

    8-K - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)

    10/29/25 11:40:48 AM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BPTH
    Leadership Updates

    Live Leadership Updates

    View All

    Bio-Path Holdings Appoints Aline Sherwood to Board of Directors

    HOUSTON, April 06, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the appointment of Aline Sherwood to its Board of Directors on March 31, 2022. Ms. Sherwood replaced Martina Molsbergen, who stepped down from the Board of Directors on February 14, 2022. "We are delighted to welcome Aline to the Bio-Path Board of Directors. With her extensive background in biotechnology communications, Aline synthesizes complex science into compelling messaging, which is instrumental in guiding our communications

    4/6/22 7:00:00 AM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BPTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Bio-Path Holdings Inc.

    SC 13G/A - BIO-PATH HOLDINGS, INC. (0001133818) (Subject)

    11/13/24 11:15:11 AM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Bio-Path Holdings Inc.

    SC 13G/A - BIO-PATH HOLDINGS, INC. (0001133818) (Subject)

    11/6/24 4:52:04 PM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Bio-Path Holdings Inc.

    SC 13G - BIO-PATH HOLDINGS INC (0001133818) (Subject)

    4/3/24 5:44:32 PM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BPTH
    Financials

    Live finance-specific insights

    View All

    Bio-Path Holdings Provides Clinical and Operational Update

    HOUSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced highlights from the recent clinical development and operational update conference call and webcast held May 26, 2025. An archived webcast of the event can be accessed here. "Our business model centers around generating new drug candidates from our DNAbilize® platform and licensing them for final development and commercialization with partners that have expertise and scale to successfully bring them to market," sa

    6/3/25 7:00:00 AM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025

    HOUSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced that it will host a live conference call and audio webcast on Thursday, May 29, 2025 at 8:30 a.m. ET to provide a comprehensive business overview. To access the live conference call, please call (844) 481-3014 (domestic) or (412) 317-1879 (international) at least five minutes prior to the start time. A live audio webcast of the call will also be available on the Presentations section of the Company's website, www.biopathho

    5/22/25 4:30:00 PM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bio-Path Holdings Reports Full Year 2024 Financial Results

    HOUSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced its financial results for the year ended December 31, 2024 and provided an update on recent corporate developments. "We are merely touching the tip of the iceberg in terms of realizing the potential of our DNAbilize® platform to change the treatment paradigm in both obesity and oncology," said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings. "Throughout the last year, we built on the bo

    3/28/25 7:00:00 AM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care